Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 4—April 2018

Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017

Mai-Juan Ma1, Cheng Liu1, Meng-Na Wu, Teng Zhao, Guo-Lin Wang, Yang Yang, Hong-Jing Gu, Peng-Wei Cui, Yuan-Yuan Pang, Ya-Yun Tan, Hui Hang, Bao Lin, Jiang-Chun Qin, Li-Qun FangComments to Author , Wu-Chun CaoComments to Author , and Li-Ling ChengComments to Author 
Author affiliations: Beijing Institute of Microbiology and Epidemiology, Beijing, China (M.-J. Ma, M.-N. Wu, T. Zhao, G.-L. Wang, H.-J. Gu, L.-Q. Fang, W.-C. Cao); University of Florida, Gainesville, Florida, USA (Y. Yang); Suzhou Municipal Center for Disease Control and Prevention, Suzhou, China (C. Liu, P.-W. Cui, Y.-Y. Pang, Y.-Y. Tan, H. Hang, B. Lin, J.-C. Qin, L.-L. Chen)

Main Article

Table 3

Proportion of influenza A(H7N9) virus survivors with titers at seroprotective levels at acute phase of infection and 3 follow-up points after infection, China, 2017*

% Patients (95% CI)
Acute phase
Follow-up visit 1
Follow-up visit 2
Follow-up visit 3
HI 54.5 (32.2–75.6) 92.0 (74.0–99.0) 82.6 (61.2–95.0) 36.4 (17.2–59.3)
NI 50.0 (28.2–71.8) 96.0 (79.6–99.9) 91.3 (72.0–98.9) 63.6 (40.7–82.8)
MN 22.7 (7.8–45.4) 88.0 (68.8–97.5) 87.0 (66.4–97.2) 86.4 (65.1–97.1)
IgG 45.5 (24.4–67.8) 100 (86.3–100) 100 (85.2–100) 100 (84.6–100)
IgA 54.5 (32.2–75.6) 96.0 (79.6–99.9) 60.9 (38.5–80.3) 59.1 (36.4–79.3)

*Seroprotective levels for HI, NI, and MN titers, >1:40; IgG >1:400; or IgA >1:50. HI, hemagglutination inhibition; MN, microneutralization; NI, neuraminidase inhibition.

Main Article

1These authors contributed equally to this article.

Page created: June 22, 2018
Page updated: June 22, 2018
Page reviewed: June 22, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.